Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035983 | 0.90 | PPARG (0.48) | PPARGMCL1KDM4EDRD2GAA | |
| SCHEMBL6035756 | 0.90 | PTGER4 (0.35) | PPARGPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL6036258 | 0.88 | SMN1; SMN2 (0.37) | PPARGPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL6035505 | 0.85 | PPARG (0.38) | ABCB1PPARGPTGER1PTGER4PTGER3 | |
| SCHEMBL6253513 | 0.85 | PTPN1 (0.43) | PPARGPPARDPPARAMCL1ALDH1A1 | |
| SCHEMBL1635158 | 0.83 | PTGER4 (0.34) | PPARGPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL6035821 | 0.80 | SMN1; SMN2 (0.36) | PPARGPPARDPPARAKDM4E | |
| SCHEMBL6035882 | 0.79 | PPARG (0.41) | PPARGPTGER4PTGER3PTGER2KDM4E | |
| SCHEMBL6035229 | 0.79 | PPARG (0.41) | ABCB1PPARGPPARDMCL1KDM4E | |
| SCHEMBL6036310 | 0.78 | PPARG (0.39) | ABCB1PPARGPPARDPPARAMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | ABCB1 262/4885PPARG 1037/4885PTGER1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.